Tepotinib not checked

Merck KGaA, Darmstadt, Germany · MSC2156119J · EMD 1214063

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
7 active
21 in total · 8 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.”In the company’s words, NCT02864992 on ClinicalTrials.gov
Tested for
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Main trialPhase 2
“This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a…”In the company’s words, NCT02864992 on ClinicalTrials.gov
Other names
MSC2156119J · EMD 1214063

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials21

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 16 May 2022 Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Phase 2Terminated 14 Mar 2022 Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
Phase 2Completed 11 May 2023 A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Phase 1/2Completed 12 Dec 2017 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Phase 1/2Completed 5 Feb 2018 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Phase 1/2Completed 14 Feb 2018 c-Met Second-Line Hepatocellular Carcinoma
Phase 1Completed 31 Oct 2015 First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Phase 1Completed 31 Mar 2016 Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
Phase 1Completed 2 Jul 2018 Effect of a Proton Pump Inhibitor on the PK of Tepotinib
Phase 1Completed 27 Aug 2018 Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
Phase 1Completed 25 Oct 2018 Effect of Tepotinib on PK of CYP3A Substrate Midazolam
Phase 1Completed 5 Feb 2019 Tepotinib Hepatic Impairment Trial
Phase 1Completed 16 Dec 2019 Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Phase 1Completed 6 May 2022 Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
Phase 1Completed 5 Jul 2022 Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants
Phase 2Authorised not given Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
Phase 2Authorised not given A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
Phase 2Authorised not given The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Phase 2Authorised not given Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy.
Phase 3Authorised not given IFCT-2404 COMET A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
Phase 2/3Authorised not given DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tepotinib

Following is part of Solo: you see every change to Tepotinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in